MAPT and Alzheimer disease: This conclusion was supported by findings from clinical trials of Aβ antibodies showing that they have slowed the cognitive decline in mild AD patients but showed no benefit in moderate cases while their brains still showed heavy distribution of tau pathology across the cortex (Selkoe and Hardy 2016).